In keeping with the newly defined mutational landscape of tumors, prostate cancer (CaP) also has extensive genetic alterations that range from single missense mutations, copy number variation, splicing variants, genetic rearrangements and short DNA alterations in a large number of genes [1], [2], [6], [7], including the androgen receptor (AR) gene. This evidence concerns the gene AR and prostate carcinoma.